Skip to content
2000
Volume 16, Issue 30
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Imidazo[1,2-a]pyridine has been shown to be an important biologically active moiety. This review is a compilation of the scattered output of results of the anticancer activities of the imidazo[1,2-a]pyridine system since 2001, which have been classified as inhibition of CDK, VEGFR, PI3K, EGFR, RGGT etc. along with inhibition against different tumor cell lines. Various imidazo[1,2-a]pyridine based analogues have been used as lead molecules and are now under human clinical trials. This review will help the wider scientific community in the area of drug discovery of imidazo[1,2-a]pyridines as novel anticancer agents.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026616666160414122644
2016-12-01
2025-09-11
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026616666160414122644
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test